Thermo Fisher Scientific (NYSE:TMO) gapped up before the market opened on Wednesday following a better than expected earnings announcement. The stock had previously closed at $208.49, but opened at $213.17. Thermo Fisher Scientific shares last traded at $214.47, with a volume of 2151118 shares changing hands.

The medical research company reported $2.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.42 by $0.08. The company had revenue of $5.85 billion for the quarter, compared to analyst estimates of $5.62 billion. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The company’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.08 EPS.

The firm also recently announced a quarterly dividend, which was paid on Monday, April 16th. Stockholders of record on Thursday, March 15th were paid a $0.17 dividend. This represents a $0.68 annualized dividend and a dividend yield of 0.32%. The ex-dividend date of this dividend was Wednesday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 7.17%.

Several brokerages have recently issued reports on TMO. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $228.00 target price on the stock in a research note on Tuesday, April 3rd. Barclays lifted their price objective on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Leerink Swann reissued an “outperform” rating and set a $239.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Thursday, February 1st. They noted that the move was a valuation call. Bank of America lifted their price objective on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. Finally, Morgan Stanley reduced their price objective on shares of Thermo Fisher Scientific from $228.00 to $216.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 11th. Two research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Thermo Fisher Scientific presently has an average rating of “Buy” and an average target price of $220.64.

In other Thermo Fisher Scientific news, SVP Gregory J. Herrema sold 33,327 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the sale, the senior vice president now directly owns 60,471 shares in the company, valued at approximately $13,285,478.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total transaction of $8,406,400.00. Following the sale, the chief executive officer now owns 334,622 shares in the company, valued at $70,324,159.52. The disclosure for this sale can be found here. Insiders have sold a total of 88,827 shares of company stock worth $19,012,672 in the last three months. 0.49% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the business. Icon Wealth Partners LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $105,000. Keeler Thomas Management LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $106,000. Virtue Capital Management LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $127,000. Premia Global Advisors LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $131,000. Finally, We Are One Seven LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $190,000. Hedge funds and other institutional investors own 87.19% of the company’s stock.

The company has a current ratio of 1.34, a quick ratio of 0.92 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $86,925.99, a P/E ratio of 22.60, a P/E/G ratio of 1.60 and a beta of 1.15.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/04/26/thermo-fisher-scientific-tmo-shares-gap-up-after-strong-earnings.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.